Twitter LinkedIn
Return to Wellspring

Communicate

Biomarker for the Detection and Monitoring of Bladder Cancer

Details

Project TitleBiomarker for the Detection and Monitoring of Bladder Cancer
Track CodeP0804
Websitehttp://musc.technologypublisher.com/technology/6649
Short Description

The inventors have developed a biomarker application based on thromboxane receptor β (TPβ), which identifies patients with various stages of bladder cancers (invasive, superficial, or metastatic).

Abstract

The inventors have developed a biomarker application based on thromboxane receptor β (TPβ), which identifies patients with various stages of bladder cancers (invasive, superficial, or metastatic). TPβ proteins are overexpressed in common bladder tumor tissue but not normal human cells. Human urine samples of patients positive for various degrees of bladder cancer confirm sensitivity approaching 93%, with 100% specificity. The detection of these proteins provide a novel, non-invasive early diagnostic method and for follow up monitoring in case of recurrence. 
 

Overview:
Bladder cancer is the fifth most common cancer in U.S. (4.6%). When detected early stage, it has a 94% survival rate. Survival rate drops to 46% after spreading to surrounding region, and declines to 6% after metastases. The gold standard for diagnosing via cystoscopy, however this is invasive, costly and is limited to interpretation bias. Other diagnostic assays, such as cystoscopy and fluorescent in situ hybridization (FISH), have limited sensitivity (50-70%). Improved sensitivity and specificity for bladder cancer would significantly increase patient survival. Also given a high recurrence rate, an easy to administer follow up procedure would be an effective clinical application in healthcare.
 
Advantages: Highly specific and selective early detection and progressive monitoring of bladder cancer
Applications: Bladder Cancer
Key Words: Bladder cancer, urine analysis, assay, specificity, selectivity, diagnostic, thromboxane receptor
 
Publications: Moussa, Omar, et al. “Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring.”  Prostaglandins Other Lipid Mediators 2011 Nov; 96(1-4):41-4.
 
Moussa, Omar, et al. “Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis.”  Cancer Research 2008 Jun 1; 68(11):4097-104.
  
Inventors: O. Moussa, D. Watson, P. Halushka
Patent Status: US Patent 8,101,371
MUSC-FRD Technology ID: P0804

 
Tagsbladder cancer, urine analysis, assay, specificity, selectivity, diagnostic, thromboxane receptor
 
Posted DateSep 27, 2016 1:17 PM

Offerings

Name Price
U.S. Issued Patent for Sale 30,000.00 USD Buy